KORU Medical posts Q3 profit, lifts 2026 revenue and margin outlook
KORU Medical Systems reported third‑quarter 2026 revenue of $11.6 million, up 11% year‑over‑year, with gross margin expanding to 65.2% and net income of $218,000. Adjusted EBITDA rose to $1.3 million, marking a second consecutive profitable quarter. The company raised its full‑year 2026 revenue guidance to $48.0‑$48.5 million and its adjusted gross‑margin target to 63%‑64%, and it now expects year‑end cash to exceed $8 million. Management highlighted new distribution agreements in Europe and Africa and continued progress on its drug pipeline.
Why it matters
The raised revenue and margin guidance suggest higher top‑line growth and profitability for the rest of 2026, which could improve cash generation and support further expansion (the company said it expects year‑end cash above $8 million). Analysts will likely adjust valuation models to reflect the higher outlook.
Key facts
- 1Q3 2026 revenue was $11.6 million, up 11% YoY. investing.com
- 2Gross margin for the quarter was 65.2%. investing.com
- 3Net income for the quarter was $218,000. investing.com
- 4Adjusted EBITDA increased to $1.3 million. investing.com
- 5Full‑year 2026 revenue outlook was raised to $48.0‑$48.5 million. finance.yahoo.com
- 6Adjusted gross‑margin target for 2026 was set at 63%‑64%. finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.